Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Wolbachia Bacteria Could Help Prevent Spread Of Zika And Dengue

XTALKS VITALS NEWS

Not only did the Wolbachia-infected mosquitoes show lower levels of the Zika virus in their saliva, but the virus isolated was not infectious.

Share this!

May 6, 2016 | by Sarah Massey, M.Sc.

A study conducted by Brazil’s Oswaldo Cruz Foundation (Fiocruz) and Eliminate Dengue, has confirmed that Wolbachia bacteria can reduce Zika virus transmission by the Aedes aegypti mosquito. The bacterial genus is currently used in regions like Australia, to control the spread of dengue.

“Zika and dengue belong in the same family of viruses so with the Zika outbreak in Brazil, the logical idea was to test the mosquitoes carrying Wolbachia by challenging them with the Zika virus,” said Dr. Luciano Moreira, senior author of the report and head of the Brazilian Eliminate Dengue team. The researchers studied wild Brazilian field mosquitoes and Wolbachia-infected mosquitoes, who were both fed blood infected with the Zika virus.

Not only did the Wolbachia-infected mosquitoes show lower levels of the Zika virus in their saliva, but the virus isolated was not infectious. The researchers are hopeful that this strategy may help block Zika virus transmission, thereby controlling the Zika epidemic.

The Wolbachia bacteria prevents replication of RNA arboviruses, including Zika, dengue and Chikungunya. As the Wolbachia infection is passed from generation to generation through the female mosquito’s egg, this approach could be a self-sustaining, less labor-intensive way to control the spread of these viruses.



This technique has been used since 2011 in Brazil, Colombia, Vietnam, Indonesia and Australia, as a way to control transmission of dengue in these at-risk countries. A trial of the Wolbachia approach in Townsville, Queensland, Australia, has reported that 80 percent of the mosquitoes have been infected with the bacteria just 18 months after it was introduced into the population.

Wolbachia is sustaining itself at high levels in the majority of these sites up to five years after application. In areas where mosquito populations have high levels of Wolbachia, we haven’t seen any significant local transmission of dengue,” said Professor Scott O’Neill from Monash University, the lead scientist for Eliminate Dengue. “The method we’re using is safe for humans and the environment, and has received widespread international support from governments, regulators and community members.”

This technology is expected to be crucial in the coming months as the Aedes aegypti vector continues to spread through Latin America, and potentially North into the Southern US states. The virus has been linked to serious neurological damage, including microcephaly, and paralysis associated with Guillain-Barré syndrome.


Keywords: Zika Virus, Epidemiology, Dengue


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.